SPEVIGO

all catalysts(0)

nothing on the calendar yet

News(3)

• Leo Pharma buys rare skin disease drug in $435M deal
  Tanabe Pharma has already asked the FDA to approve the medicine for two conditions that cause severe reactions to sunlight.
  biopharma_dive · 2d ago
• LEO adds to dermatology portfolio with $435M deal for late-stage rare disease drug
  This is the third recent acquisition conducted by Denmark’s LEO Pharma in medical dermatology, a portfolio that marked 12% growth in the first half of the year.
  biospace · 2d ago
• Leo ‘really strengthening’ pipeline with $435M deal for Tanabe rare skin disease drug awaiting FDA nod
  Leo Pharma is sticking to its mission of strengthening its pipeline in 2026, penning a $435 million deal for a rare skin disease drug from Tanabe Pharma that's awaiting an approval decision by the…
  fiercebiotech · 4d ago